Background Axial spondyloarthritis (axSpA) impairs trunk strength, mobility and cardiorespiratory fitness. Despite exercise ...
FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM ...
The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with ...
Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA ...
Data from cardiopulmonary exercise testing (CPET) provides important information about the functional status of patients with a range of congenital heart disease (CHD). CPET data in patients with CHD, ...
Two recent case series describe the use of invasive implanted hemodynamic monitoring (IHM) with the CardioMEMS™ HF System (Abbott Laboratories, Abbott Park, Illinois) in pediatric patients. IHM can be ...
England beat Australia by four wickets in two-day Test at Melbourne to avoid Ashes whitewash; Jacob Bethell top-scores in England second innings; tourists 3-1 down ahead of final Test in Sydney from ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approv ...
Psychology Today's online self-tests are intended for informational purposes only and are not diagnostic tools. Psychology Today does not capture or store personally identifiable information, and your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback